Blog

HER2-Low Status and Its Impact on Outcomes in Early-Stage Triple-Negative Breast Cancer

breast cancer/narayanahealth.org

Nov 13, 2024, 11:56

HER2-Low Status and Its Impact on Outcomes in Early-Stage Triple-Negative Breast Cancer

Elisabetta Bonzano, Radiation Oncologist at IRCCS San Matteo Polyclinic Foundation, shared a post on X:

“ Clinical outcomes of early-stage triple-negative breast cancer after neoadjuvant chemotherapy according to HER2-low status

Authors: A.S. Raghavendra, D.B. Zakon, Q. Jin, A. Strahan, M. Grimm, M.E. Hughes, M. Cherian, J. Vincuilla, T. Parker, P. Tarantino, E.A. Mittendorf, T.A. King, V. Valero, D. Tripathy, S.M. Tolaney, N. Tayob, N.U. Lin, D.G. Stover, C.H. Barcenas, A.C. Garrido-Castro

HER2-low eTNBC showed no pCR or survival benefit over HER2 IHC score 0.

RFS did not significantly differ between HER2 IHC categories after NAT.

HER2-low tumors had higher nodal positivity (55%) than HER2 IHC score 0 (46.6%); P = 0.011.

Post-treatment HER2 IHC status changed in 31.1% of HER2 IHC score 0 and 34.8% of HER2-low cases.

HER2 IHC status discordance underscores quantification and heterogeneity challenges.“

A. Strahan A.C. Garrido-Castro A.S. Raghavendra Breast Cancer C.H. Barcenas cancer D. Tripathy D.B. Zakon D.G. Stover E.A. Mittendorf Elisabetta Bonzano J. Vincuilla M. Cherian M. Grimm M.E. Hughes N. Tayob N.U. Lin OncoDaily Oncology P. Tarantino Q. Jin S.M. Tolaney T. Parker T.A. King V. Valero

Mark Ruffalo and Brain Cancer: How He Went Against, How He Survived, and More

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

FDA approves Methotrexate for Pediatric acute Lymphoblastic Leukemia

Special Coverage